Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP & General Mgr, Industrial | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,673 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 2,552 · Balance 21,673 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 12,376 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,376 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,129 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,129 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $564.54 | $1,693,620.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,025 F8 · price: Represents volume-weighted average price of sales of 3,000 shares of Company stock on May 7, 2020 at prices ranging from $564.04 to $564.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,195 | $563.58 | $1,237,058.10 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,025 F7 · price: Represents volume-weighted average price of sales of 2,195 shares of Company stock on May 7, 2020 at prices ranging from $563.00 to $563.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,077 | $562.45 | $1,168,208.65 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,220 F6 · price: Represents volume-weighted average price of sales of 2,077 shares of Company stock on May 7, 2020 at prices ranging from $562.03 to $562.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,988 | $561.55 | $2,801,011.40 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,297 F5 · price: Represents volume-weighted average price of sales of 4,988 shares of Company stock on May 7, 2020 at prices ranging from $561.00 to $561.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,231 | $560.53 | $1,811,072.43 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,285 F4 · price: Represents volume-weighted average price of sales of 3,231 shares of Company stock on May 7, 2020 at prices ranging from $560.00 to $560.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $559.20 | $279,600.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,516 F3 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on May 7, 2020 at prices ranging from $559.05 to $559.36. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,118 | $558.43 | $1,182,754.74 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,016 F2 · price: Represents volume-weighted average price of sales of 2,118 shares of Company stock on May 7, 2020 at prices ranging from $558.02 to $558.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $557.59 | $334,554.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,134 F1 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on May 7, 2020 at prices ranging from $557.13 to $557.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $556.92 | $55,692.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,734 Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · derivative · entry 21 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: With respect to 33,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 52,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 33,079 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · derivative · entry 20 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 33,079 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: With respect to 33,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 52,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 28,217 | $555.77 | $15,682,162.09 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,834 Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 52,500 | $52.03 | $2,731,575.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 17,779 | $555.77 | $9,881,034.83 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,551 Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 33,079 | $52.03 | $1,721,100.37 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 210 | $460.30 | $96,663.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 F10 · price: Represents volume-weighted average price of sales of 210 shares of Company stock on February 26, 2020 at prices ranging from $460.00 to $460.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,425 | $459.33 | $654,545.25 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,461 F9 · price: Represents volume-weighted average price of sales of 1,425 shares of Company stock on February 26, 2020 at prices ranging from $459.02 to $459.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,274 | $458.45 | $2,417,865.30 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,886 F8 · price: Represents volume-weighted average price of sales of 5,274 shares of Company stock on February 26, 2020 at prices ranging from $458.00 to $458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,787 | $457.59 | $1,732,893.33 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,160 F7 · price: Represents volume-weighted average price of sales of 3,787 shares of Company stock on February 26, 2020 at prices ranging from $457.00 to $457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,435 | $456.50 | $655,077.50 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,947 F6 · price: Represents volume-weighted average price of sales of 1,435 shares of Company stock on February 26, 2020 at prices ranging from $456.00 to $456.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,300 | $455.50 | $592,150.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,382 F5 · price: Represents volume-weighted average price of sales of 1,300 shares of Company stock on February 26, 2020 at prices ranging from $455.01 to $455.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 711 | $454.53 | $323,170.83 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,682 F4 · price: Represents volume-weighted average price of sales of 711 shares of Company stock on February 26, 2020 at prices ranging from $454.02 to $454.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $453.57 | $453,570.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,393 F3 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 26, 2020 at prices ranging from $453.06 to $453.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $452.53 | $135,759.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,393 F2 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on February 26, 2020 at prices ranging from $452.25 to $452.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $451.61 | $90,322.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,693 F1 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on February 26, 2020 at prices ranging from $451.51 to $451.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 32,735 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · derivative · entry 14 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,735 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 17,093 | $447.30 | $7,645,698.90 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,893 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 32,735 | $30.63 | $1,002,673.05 |
DisclosureSEC source: 0001708138-20-000014 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000032 · edgardoc.xml · derivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-12-11 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000032 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 F2 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 11, 2023. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000032 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,251 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 46,250 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001708138-18-000028 · edgardoc.xml · derivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 46,250 shares Expires 2028-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000029 · edgardoc.xml · derivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000091 · edgardoc.xml · derivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.